Zoetis Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Zoetis Inc. (ZTS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $8.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-12
- Zoetis Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $8.00M, a 80.00% decline from fiscal 2024.
- Zoetis Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $40.00M, a 50.62% decline from fiscal 2023.
- Zoetis Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $81.00M, a 161.29% increase from fiscal 2022.
- Zoetis Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $31.00M, a 64.37% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2025-12-31 | $8.00M 10-K · filed 2026-02-12 |
| 2024-12-31 | $40.00M 10-K · filed 2026-02-12 |
| 2023-12-31 | $81.00M 10-K · filed 2026-02-12 |
| 2022-12-31 | $31.00M 10-K · filed 2025-02-13 |
| 2021-12-31 | $87.00M 10-K · filed 2024-02-13 |
| 2020-12-31 | $114.00M 10-K · filed 2023-02-14 |
| 2019-12-31 | $76.00M 10-K · filed 2022-02-15 |
| 2018-12-31 | $66.00M 10-K · filed 2021-02-16 |
| 2017-12-31 | $32.00M 10-K · filed 2020-02-13 |
| 2016-12-31 | $23.00M 10-K · filed 2019-02-14 |
| 2015-12-31 | $5.00M 10-K · filed 2018-02-15 |
| 2014-12-31 | $1.00M 10-K · filed 2017-02-16 |
| 2013-12-31 | $0.00 10-K · filed 2015-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |